Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.50
+0.19
(+2.04%)
After-Hours: 20:00
Monte Rosa Therapeutics Max Drawdown (5Y) : 94.08% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 94.08% |
| September 30, 2026 | 94.08% |
| August 31, 2026 | 94.08% |
| July 31, 2026 | 94.08% |
| June 30, 2026 | 94.08% |
| May 31, 2026 | 94.08% |
| April 30, 2026 | 94.08% |
| March 31, 2026 | 94.08% |
| Date | Value |
|---|---|
| February 28, 2026 | 94.08% |
| January 31, 2026 | 94.08% |
| December 31, 2025 | 94.08% |
| November 30, 2025 | 94.08% |
| October 31, 2025 | 94.08% |
| September 30, 2025 | 94.08% |
| August 31, 2025 | 94.08% |
| July 31, 2025 | 94.08% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| United Therapeutics Corp. | 33.00% |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 66.41% |
| Anika Therapeutics, Inc. | 83.15% |
| Savara, Inc. | 93.79% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -29.82 |
| Beta (5Y) | 1.405 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 95.42% |
| Historical Sharpe Ratio (5Y) | -0.1916 |
| Historical Sortino (5Y) | -0.4693 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 33.59% |